I was at a cancer presentation and a doctor from Sloan-Kettering mentioned this as a very promising drug, I think he was referring to prostate cancer so it has more indications.
This shows you that if Roche wasn't involved and a smaller company was in control of the drug, they would have gone into phase 2 with the wrong dose and it would have been a failed drug.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.